Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of PR104 in Subjects With Refractory/Relapsed Acute Leukemia Using Adaptive Dose Selection

NCT01037556 is registered in ClinicalTrials.gov with Proacta, Incorporated as lead sponsor.

NCT NCT01037556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01037556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of PR104 in Subjects With Refractory/Relapsed Acute Leukemia Using Adaptive Dose Selection
Lead sponsor
Proacta, Incorporated
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 31, 2010
Completion date
December 31, 2012
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia, acute myelogenous leukemia